Literature DB >> 6259296

Lymphocyte blast transformation responses and viral antibodies in relation to HLA antigens in multiple sclerosis.

J Ilonen, M Reunanen, A Salmi, A Tiilikainen.   

Abstract

Fifty four clinically stable multiple sclerosis (MS) patients and 54 age- and sex-matched control subjects were HLA-typed, and their responses to herpes simplex, measles, mumps and rubella antigens were examined by the lymphocyte blast transformation test and by serum antibody titrations. Blast transformation response to purified tuberculin (PPD), mitogen phytohaemagglutinin (PHA), pokeweed mitogen (PWN) and concanavalin A (Con A) and spontaneous proliferation of lymphocytes were also studied. MS patients differed from controls by higher antibody levels to measles and rubella viruses and by lower specific blast transformation responses to rubella and measles antigens. When the relative strength of transformation responses was measured, mumps and herpes simplex responses were also lower in MS patients than in controls. In addition, spontaneous lymphocyte proliferation of MS patients in 6-day cultures was lower than that of control lymphocytes. In mitogen stimulations there were no differences between whole groups, but the oldest patients had lower responses to PHA and Con A than their matched controls. The frequency of HLA-Dw2 was 56.6% in MS patients and 32.1% in controls. The patients with and without Dw2 differed from each other only by a lower specific response to PPD in the Dw2-positive group. The immunological response of Dw2-positive controls resembled that of MS patients: low transformation response to viral antigens, low spontaneous proliferation and elevated measles antibodies. This finding supports the function of a genetically determined type of immune responsiveness with low cell-mediated immunity and high levels of certain viral antibodies as one susceptibility factor in multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6259296     DOI: 10.1016/0022-510x(81)90194-5

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  8 in total

1.  Evidence of an accelerated B-cell destruction in HLA-Dw3/Dw4 heterozygous children with type 1 (insulin-dependent) diabetes.

Authors:  M Knip; J Ilonen; A Mustonen; H K Akerblom
Journal:  Diabetologia       Date:  1986-06       Impact factor: 10.122

2.  Defective erythrocyte C3b receptor function associated with low serum complement (C3, C4) concentrations in insulin-dependent diabetes mellitus.

Authors:  P Ruuska; J Ilonen; A Mustonen; A Tiilikainen
Journal:  Clin Exp Immunol       Date:  1984-07       Impact factor: 4.330

3.  Immunological parameters in multiple sclerosis patients with special reference to the herpes virus group.

Authors:  S Haahr; A Møller-Larsen; E Pedersen
Journal:  Clin Exp Immunol       Date:  1983-02       Impact factor: 4.330

4.  Cell number requirements for lymphocyte stimulation in vitro: changes during the course of multiple sclerosis and the effects of immunosuppression.

Authors:  S C Knight; B Harding; S Burman; J Mertin
Journal:  Clin Exp Immunol       Date:  1981-10       Impact factor: 4.330

5.  Intrathecal antibody synthesis to virus antigens in multiple sclerosis.

Authors:  A Salmi; M Reunanen; J Ilonen; M Panelius
Journal:  Clin Exp Immunol       Date:  1983-05       Impact factor: 4.330

6.  Radioimmunoprecipitation and immunoblot studies of antibodies to rubella virus in patients with chronic liver disease.

Authors:  M B Kalvenes; K H Kalland; G Haukenes
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

7.  Increased B cell and cytotoxic NK cell proportions and increased T cell responsiveness in blood of natalizumab-treated multiple sclerosis patients.

Authors:  Johan Mellergård; Måns Edström; Maria C Jenmalm; Charlotte Dahle; Magnus Vrethem; Jan Ernerudh
Journal:  PLoS One       Date:  2013-12-02       Impact factor: 3.240

Review 8.  Abnormalities of serum and plasma components in patients with multiple sclerosis.

Authors:  H C Ford
Journal:  Clin Biochem       Date:  1985-02       Impact factor: 3.281

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.